NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Clinical Trials
32 trialsNCT04466891 2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2 Completed
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT03201458 2024-04-05
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03833661 2023-10-25
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Phase 2 Completed
NCT04072445 2023-08-09
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
Phase 2 Completed
NCT03278106 2023-06-28
TAS-102 in Treating Advanced Biliary Tract Cancers
Mayo Clinic
Phase 2 Completed
NCT02520141 2023-06-15
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02392637 2022-02-02
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02115542 2021-10-12
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02631590 2021-08-04
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00478140 2019-08-20
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02053376 2019-01-30
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
University of Pittsburgh
Phase 2 Completed
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00789958 2018-04-09
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
SWOG Cancer Research Network
Phase 2 Completed
NCT00903396 2017-11-24
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00033540 2017-09-12
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
SWOG Cancer Research Network
Phase 2 Completed
NCT02042443 2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085410 2017-07-02
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01007552 2017-03-29
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Roswell Park Cancer Institute
Phase 2 Completed
NCT01229111 2017-03-29
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT01151761 2016-07-29
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Stanford University
Phase 2 Terminated
NCT01425879 2016-06-17
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00919061 2016-02-03
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00075504 2015-09-28
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01093222 2015-06-30
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00660699 2015-05-27
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
Washington University School of Medicine
Phase 2 Completed
NCT00107536 2015-04-29
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00356889 2014-05-28
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00338988 2012-08-01
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Completed